Skip to content
Screener

Pre-Tax Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.09B+130%
Eli Lilly logo
Eli LillyLLY
$9.25B+36.4%
Amgen logo
AmgenAMGN
$2.77B+76.5%
Incyte logo
IncyteINCY
$751.51M+34.7%
AbbVie logo
AbbVieABBV
$4.28B+175%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$74.03M-34.0%

Other financials

Income statement

See full
Revenue$213.5M+3,749%
Operating income$158.8M+478%
Net income$162.8M+568%
EPS (diluted)$2.29+516%

Balance sheet

See full
Cash & equivalents$420.1M+149%
Total debt$9.2M-18.3%
Total equity$841.5M+26.0%
Total assets$885.5M+23.3%

Cash flow

See full
Operating cash flow$219.1M
CapEx$168.0K-79.3%
Free cash flow$218.9M

Valuation

See full
Market cap$8.83B+165%
Enterprise value$8.42B+165%
P/E106.5×+42.4×
P/S31.3×+15.4×

Profitability

See full
Operating margin20.7%+9.2pp
Net margin29.4%+4.5pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity11%+2.4pp
Debt / equity0.0×
Current ratio21.7×+4.7×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091123
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Income (loss) from operations158,766(42,041)155,118(61,351)
Interest income6,4297,40612,30514,979
Other (expense) income, net(81)36(28)118
Income (loss) before income tax expense165,114(34,599)167,395(46,254)
Income tax expense2,265172763172
Net income (loss)$162,849$(34,771)$166,632$(46,426)
Net income (loss) per share, basic$2.47$(0.55)$2.54$(0.73)
Net income (loss) per share, diluted$2.29$(0.55)$2.35$(0.73)

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Protagonist Therapeutics's pre-tax income?
Protagonist Therapeutics (PTGX) reported pre-tax income of $165.11M in Q2 2026.
How has Protagonist Therapeutics's pre-tax income changed year-over-year?
Protagonist Therapeutics's pre-tax income increased by 577.2% year-over-year, from -$34.6M to $165.11M.
What is the long-term trend for Protagonist Therapeutics's pre-tax income?
Over 3 years (2021 to 2025), Protagonist Therapeutics's pre-tax income has grown at a 1.0% compound annual growth rate (CAGR), from -$125.55M to -$129.31M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Protagonist Therapeutics's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude